Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + idarubicin + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Daunorubicin + idarubicin + mitoxantrone is a combination chemotherapy regimen comprising three cytotoxic agents: daunorubicin and idarubicin (both anthracyclines) and mitoxantrone (an anthracenedione). This combination is utilized as an investigational salvage therapy arm within a prospective, multicenter, platform-type clinical study for patients with refractory or relapsed acute myeloid leukemia (AML). Each component acts as a small molecule topoisomerase II inhibitor and DNA intercalator, disrupting DNA replication and transcription to induce apoptosis in rapidly dividing malignant cells. The regimen is being evaluated for its efficacy, safety, and impact on overall survival by the Institute of Hematology & Blood Diseases Hospital in China.
- Other names
- DIM regimenDIM
02
Targets
DNATOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin + idarubicin + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + idarubicin + mitoxantrone.